The Journal of Heart and Lung Transplantation
Volume 29, Issue 5 , Pages 523-530 , May 2010

Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation

  • Víctor Monforte, MD

      Affiliations

    • Respiratory Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
    • Ciber Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
    • Corresponding Author InformationReprint requests: Víctor Monforte, MD, Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Telephone: +34-93-2746157. Fax: +34-93-2746083
    • ,
  • Piedad Ussetti, MD

      Affiliations

    • Respiratory Department, Hospital Universitario Puerta de Hierro, Madrid, Spain
    • ,
  • Joan Gavaldà, MD

      Affiliations

    • Infectious Disease Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
    • ,
  • Carles Bravo, MD

      Affiliations

    • Respiratory Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
    • Ciber Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
    • ,
  • Rosalia Laporta, MD

      Affiliations

    • Respiratory Department, Hospital Universitario Puerta de Hierro, Madrid, Spain
    • ,
  • Oscar Len, MD

      Affiliations

    • Infectious Disease Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
    • ,
  • Cristina López García-Gallo, MD

      Affiliations

    • Respiratory Department, Hospital Universitario Puerta de Hierro, Madrid, Spain
    • ,
  • Lluís Tenorio, MD

      Affiliations

    • Intensive Care Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
    • ,
  • Joan Solé, MD

      Affiliations

    • Thoracic Surgery Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
    • ,
  • Antonio Román, MD

      Affiliations

    • Respiratory Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
    • Ciber Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain

References 

  1. Yeldandi V, Laghi F, McCabe MA, et al. Aspergillus and lung transplantation. J Heart Lung Transplant. 1995;14:883–890
  2. Westney GE, Kesten S, de Hoyos A, et al. Aspergillus infection in single and double lung transplant recipients. Transplantation. 1996;61:915–919
  3. Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997;112:1160–1164
  4. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis. 1998;26:753–755
  5. Mehrad B, Paciocco G, Martinez FJ, et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest. 2001;119:169–175
  6. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003;22:258–266
  7. Sole A, Morant P, Salavert M, et al. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect. 2005;11:359–365
  8. Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc. 1997;26:627–628
  9. Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant. 2001;20:1274–1281
  10. Drew RH, Dodds AE, Benjamin DK, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation. 2004;77:232–237
  11. Mohammad RA, Klein KC. Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections. Ann Pharmacother. 2006;40:2148–2154
  12. Lowry CM, Marty FM, Vargas SO, et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis. 2007;9:121–125
  13. Dummer JS, Lazariashvilli N, Barnes J, et al. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant. 2004;23:1376–1381
  14. Husain S, Zaldonis D, Kusne S, et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis. 2006;8:213–218
  15. Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation. 2003;75:1571–1574
  16. Monforte V, Ussetti P, Lopez R, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant. 2009;28:170–175
  17. Juarez JC, Lopez RM, Hueto M, et al. Stability of amphotericin B in water solution for inhalation. Eur Hosp Pharm. 1997;3:59–60
  18. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–1097
  19. Trulock EP. Lung transplantation. Am J Respir Crit Care Med. 1997;155:789–818
  20. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21:297–310
  21. Calvo V, Borro JM, Morales P, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation (Valencia Lung Transplant Group). Chest. 1999;115:1301–1304
  22. Guillemain R, Lavarde V, Amrein C, et al. Invasive aspergillosis after transplantation. Transplant Proc. 1995;27:1307–1309
  23. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis. 2002;4:195–200
  24. Borro JM, Sole A, de la TM, et al. Efficiency and safety of inhaled amphotericin B lipid complex (abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc. 2008;40:3090–3093
  25. Gavalda J, Len O, Juan RS, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study. Clin Infect Dis. 2005;41:52–59
  26. Hamacher J, Spiliopoulos A, Kurt AM, et al. Pre-emptive therapy with azoles in lung transplant patients (Geneva Lung Transplantation Group). Eur Respir J. 1999;13:180–186
  27. Mattner F, Chaberny IF, Weissbrodt H, et al. [Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole]. Mycoses. 2005;48(Suppl 1):51–55
  28. Shitrit D, Ollech JE, Ollech A, et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J Heart Lung Transplant. 2005;24:2148–2152
  29. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6:3008–3016
  30. Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40:89–99
  31. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis. 2003;16:607–612
  32. Aguilar-Guisado M, Givalda J, Ussetti P, et al. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant. 2007;7:1989–1996
  33. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation. 2001;72:545–548
  34. Bates DW, Yu DT. Clinical impact of drug-drug interactions with systemic azole antifungals. Drugs Today (Barc). 2003;39:801–813
  35. Monforte V, Román A, Gavaldà J, et al. Contamination of the nebulization systems used in the prophylaxis with amphotericin B nebulized in lung transplantation. Transplant Proc. 2005;37:4056–4058
  36. Kramer MR, Denning DW, Marshall SE, et al. Ulcerative tracheobronchitis after lung transplantation (A new form of invasive aspergillosis). Am Rev Respir Dis. 1991;144:552–556
  37. Nathan SD, Shorr AF, Schmidt ME, et al. Aspergillus and endobronchial abnormalities in lung transplant recipients. Chest. 2000;118:403–407
  38. Ruiz I, Gavalda J, Monforte V, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant. 2006;6:178–182
  39. Helmi M, Love RB, Welter D, et al. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest. 2003;123:800–808
  40. Danziger-Isakov LA, Worley S, Arrigain S, et al. Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation. J Heart Lung Transplant. 2008;27:655–661
  41. Ruffini E, Baldi S, Rapellino M, et al. Fungal infections in lung transplantation (Incidence, risk factors and prognostic significance). Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:181–190
  42. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781–803
  43. Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis. 2007;26:879–886
  44. Agencia Española del Medicamento y Productos Sanitarios. GPT 1 Guía de Prescripción Terapéutica (Adaptación española del British National Formulary). Primera ed. Barcelona. 2006;321–326

PII: S1053-2498(09)01507-1

doi: 10.1016/j.healun.2009.11.603

The Journal of Heart and Lung Transplantation
Volume 29, Issue 5 , Pages 523-530 , May 2010

Article Tools

* Image Usage & Resolution